Therapeutic Effect and Prognostic Analysis of Induction Chemotherapy with Idarubicin/BH-AC in Acute Myelogenous Leukemia.
- Author:
Je Jung LEE
1
;
Ik Joo CHUNG
;
Duc Hwan YANG
;
Sang Hee CHO
;
Tae Young YANG
;
Hyeong Cheon PARK
;
Moo Rim PARK
;
Hyeoung Joon KIM
Author Information
1. Department of Internal Medicine, Chonnam National University Medical School, Kwangju, Korea.
- Publication Type:Original Article
- Keywords:
Acute myelogenous leukemia;
Combination chemotherapy;
Idarubicin;
BH- AC;
Prognostic factor
- MeSH:
Chromosome Aberrations;
Disease-Free Survival;
Drug Therapy;
Drug Therapy, Combination;
Humans;
Idarubicin;
Induction Chemotherapy*;
Jeollanam-do;
Leukemia, Myeloid, Acute*;
Remission Induction;
Survival Rate
- From:Korean Journal of Hematology
2000;35(2):109-116
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: We have analyzed the outcome and prognostic factors for 61 patients with acute myelogenous leukemia (AML) who were treated with idarubicin(IDA)/N 4-behenoyl- 1-beta-D-arabinofuranosylcytosine(BH-AC) regimen at Chonnam National University Hospital between April 1994 and December 1998. METHODS: Fifty-six patients with newly diagnosed AML and 5 patients failed by IDA/ara- C were eligible to analysis. Remission induction chemotherapy consisted of IDA (12 mg/m2/day IV over 30 minutes on days 1~3) and BH-AC (age < or =40 years: 300 mg/m2/day IV over 4 hours on days 1~7; age >40 years: 200 mg/m2/day). After achievement of a complete remission (CR), four polychemotherapy cycles, allogeneic BMT or autologous PBSCT were given as consolidation. RESULTS: Median age was 38 years (range, 17 to 65). Of 61 patients, 43 (70.5%) achi-eved CR and 6 (9.8%) died of early complications. The Kaplan-Meier estimated overall survival rate was 51.8+/-7.7%, 43.1+/-8.5% and 29.6+/-8.8% at 1 year, 2 year and 3 year respectively, and the disease free survival rate was 58.4+/-9.7%, 43.3+/-10.4% and 24.0+/-12.2 % at 1 year, 2 year and 3 year, respectively. Unfavorable prognostic variables for achieving CR were age >55 years (P =0.006), FAB subtypes (P=0.005) and poor risk cytogenetic abnormalities (P=0.021), and FAB subtypes for overall survival (P=0.0064). CONCLUSION: IDA/BH-AC combination chemotherapy is an effective and well-tolerated regimen for induction treatment of AML.
